30
Participants
Start Date
March 15, 2017
Primary Completion Date
September 9, 2020
Study Completion Date
February 9, 2021
Obinutuzumab
Type II anti-CD20 monoclonal antibody
Gemcitabine
Antineoplastic agent
Dexamethasone
Corticosteroid
Cisplatin
Antineoplastic Agent
Princess Margaret Cancer Centre, Toronto
Collaborators (1)
Hoffmann-La Roche
INDUSTRY
Ozmosis Research Inc.
INDUSTRY
University Health Network, Toronto
OTHER